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Division of Maternal Fetal Medicine, Lehigh Valley Health Network, Allentown, PA, United States
Use of Commercial Tests for Aneuploidy Screening Using Cell-free Fetal DNA
in Clinical Practice
Adetola Louis-Jacques, Courtney Burans, Sara Robinson, Elizabeth Schofield, Joanne Quinones, John Smulian, Meredith Rochon
INTRODUCTION:
In the past two decades, numerous strategies for the detection 
of fetal aneuploidy have been developed, although definitifve 
diagnosis is possible only through the use of invasive 
procedures. In the fall of 2011, non-invasive tests for the 
diagnosis of common aneuploidies first became commercially 
available for the diagnosis of common trisomies and sex 
chromosome abnormalities. These tests work by identifying 
cffDNA in maternal blood with a high degrees of sensitivity and 
specificity, and have the advantage of providing the patient 
with highly accurate information without the discomfort or 
risk of an invasive procedure. The purpose of this study is to 
characterize the use of cell-free fetal DNA tests used at our 
institution for women at high risk for fetal aneuploidy. 
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METHODS:
 •  Retrospective cohort study of all women undergoing cffDNA 
testing through Lehigh Valley Health Network Maternal Fetal 
Medicine practice from 1/1/12 to 6/30/12.  
	 	 –		CffDNA testing was offered only to women at high risk for 
aneuploidy based on maternal age, abnormal screening results, 
abnormal ultrasound findings, and/or family/personal history of 
aneuploidy. 
	 	 –		All women underwent genetic counseling prior to cffDNA 
testing.
	 	 –		Women with positive results were  strongly encouraged to 
undergo invasive testing to confirm results. 
 •  Women were identified by review of a MFM clinical 
database developed to track patients that underwent cffDNA 
testing. 
 •  Medical records were reviewed for baseline characteristics, 
indications for testing, test results and pregnancy outcomes. 
Neonatal records were reviewed when available.
 •  Descriptive statistics were generated for baseline 
characteristics and test indications. Sensitivity, specificity, 
positive predictive value and negative predictive value were 
calculated for trisomies 13, 18 and 21. 
RESULTS:
CONCLUSIONS:
Our study provides some information on the 
use of new commercial tests for aneuploidy 
screening using cffDNA in clinical practice in a 
non-research setting. Although the potential for 
these tests to provide women with information 
regarding their pregnancies without the 
risk of an invasive procedure is exciting, 
additional studies are needed to validate 
their performance in both low and high risk 
populations, and providers and patients need 
to be aware of their limitations.
ABSTRACT:
Objective: To characterize the use of the new 
commercial tests for aneuploidy screening using cell-
free fetal DNA (cffDNA) by women at high risk for fetal 
aneuploidy.
Study Design: This is a retrospective cohort study of 
all women undergoing cffDNA testing in the first 6 months 
the tests were offered in the Lehigh Valley Health Network 
Maternal Fetal Medicine practice. All patients were high 
risk for fetal aneuploidy defined as advanced maternal 
age, abnormal aneuploidy screening, abnormal ultrasound 
findings and/or personal/family history. Medical records 
were reviewed for patient demographics, indication for 
testing, other tests performed, pregnancy outcomes 
(maternal and fetal) and insurance information.
Results: A total of 142 patients underwent cffDNA testing 
from 1/1/12 to 6/30/12. The mean age of patients having 
the test performed was 32.3 ± 6.5 years. Most patients 
were Caucasian (72%), non-hispanic (83%), multiparous 
(64%), married (58%), had private obstetrician (77%), had 
private insurance (51%) and were singleton gestations 
(95%). The median gestational age the test was performed 
was 18 5/7 weeks (range 10 2/7 – 28 3/7). Most tests 
were performed in the second trimester (73%). Insurance 
coverage varied and evolved significantly during this time 
period. Four patients had positive test results (3%) and 
three had uninformative results (2%). There was one false 
negative and there were no false positives. Sensitivity, 
specificity, positive predictive value and negative predictive 
value were 80%, 100%, 100% and 99%, respectively.
Conclusion: Our study provides some information on 
the use of new commercial tests for aneuploidy screening 
using cffDNA in clinical practice in a non-research setting. 
Although the potential for these tests to provide women 
with information regarding their pregnancies without the 
risk of an invasive procedure is exciting, additional studies 
are needed to validate their performance in both low and 
high risk populations, and providers and patients need to 
be aware of their limitations.
Table 1. Baseline Characteristics of Women Undergoing 
Cell-free Fetal DNA Testing*
Mean maternal age (years) 32.3±6.5
Advanced maternal age 73/141 (52%)
Ethnicity 
   Caucasian 102/142 (72%)
   Black 10/142 (7%)
   Asian/Indian 8/142 (6%)
   American Indian 3/142 (2%)
   Arabic 1/142 (1%)
   Mixed 3/142 (2%)




Private obstetrician 102/132 (77%)
Private insurance 65/127 (51%)
Singleton gestation 125/132 (95%)
High school graduate 85/95 (89%)
College graduate 40/95 (42%)





* Not all characteristics available for all subjects
Data in n (%), mean +SD or median (range). GA, gestational age.
Table 2. Primary Indications for Cell-free                      
 Fetal DNA Testing
AMA only 26 (18%)
Abnormal screen only 41 (29%)
Abnormal ultrasound only 52 (37%)
Abnormal screen and abnormal ultrasound 19 (13%)
History indicated 3 (2%)
Unspecified 1 (1%)
Data are in n (%). 
Table 3. Summary of Cell-free Fetal DNA Results
135 negative 
•  One false negative. Indication: abnormal serum screen, increased 
nuchal translucency and AMA. No major structural abnormalities.  
Diagnosis of trisomy 21 suspected at delivery and confirmed by 
postnatal karyotype. 
 
4 Positive for Trisomy 21
 •  Indication: AMA only. IVF pregnancy started as di/di twin gestation with 
embryonic demise of Twin A in first trimester. Remaining fetus had no 
abnormalities on ultrasound. Declined amniocentesis. Opted to continue 
pregnancy. Delivered healthy child. Suspect demise twin to be source of 
aneuploidy. No karyotype done on placenta. 
•  Indication: cystic hygroma. Declined amniocentesis. Opted to continue 
the pregnancy. Duodenal atresia and CHD suspected prenatally and 
confirmed postnatally. Delivered at 31 weeks for abnormal antenatal 
testing, trisomy 21 confirmed.  
•  Indication: increased NT. Declined amniocentesis. Opted to continue 
pregnancy. CHD subsequently suspected on ultrasound. CHD and 
trisomy 21 confirmed postnatally.  
•  Indication:  CHD at time of level 2 ultrasound. Confirmed with 
amniocentesis. Pregnancy terminated. 
AMA, advanced maternal age. CHD, congenital heart disease.
Table 4. Performance of Cell-free Fetal DNA Tests to 
Detect Trisomy 13, 18,21
Sensitivity 80%
Specificity 100%
Positive Predictive Value 100%
Negative Predictive Value 99%
